ATXS | Astria Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	9.26 - 9.81
52 Week Range	6.20 - 16.90
Beta	0.10
Implied Volatility	165.59%
IV Rank	15.45%
Day's Volume	792,983
Average Volume	317,885
Shares Outstanding	56,434,200
Market Cap	539,510,952
Sector	Healthcare
Industry	Biotechnology
IPO Date	2015-06-25

Valuation
Profitability
Growth
Health
P/E Ratio	-4.39
Forward P/E Ratio	N/A
EPS	-2.18
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	59
Country	USA
Website	ATXS

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.

ATXS's peers: ANEB, ADAG, ACRV, ANAB, MLYS, AVTE, RZLT, ANTX, OLMA, IRON, LRMR, FENC, OBIO, OPT

*Chart delayed

Analyzing fundamentals for ATXS we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see ATXS Fundamentals page.

Watching at ATXS technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on ATXS Technicals page.